Public-private partnership launched to develop new drugs for roundworm infections

in

“Pan-nematode” drug development platform is part of Europe’s Horizon 2020 programme

A new consortium of research institutes, universities, not-for-profit organizations, and pharmaceutical companies has teamed up to develop novel drugs for infections caused by parasitic worms (helminths), a debilitating group of diseases that includes river blindness, lymphatic filariasis, as well as infection with hookworm and whipworm, which together affect close to a billion people.

[Deutsch]

Called the Helminth Elimination Platform (HELP), this new multidisciplinary platform is funded through the European Union’s Horizon 2020 research and innovation programme and will run to September 2024. HELP is led by the Swiss Tropical and Public Health Institute (Swiss TPH), and comprises not-for-profit research and development (R&D) organization, Drugs for Neglected Diseases initiative (DNDi), and pharmaceutical companies, Bayer Animal Health and Bristol-Myers Squibb (formerly Celgene). Partnering European and African academic institutions are the University Hospital Bonn, Germany, and Muséum National d’Histoire Naturelle Paris, France, as well as the Ifakara Health Institute, Tanzania, and the University of Buea, Cameroon.

Read full article here: Helminth Elimination Platform (HELP)

Date: 
Thursday, November 28, 2019 - 12:00

Back to top